Afficher la couverture 'Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756) | Calleris, Giorgio' en grand format
/5

0 avis

Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756)

Archive ouverte

Calleris, Giorgio | Roupret, Morgan | Seisen, Thomas | Bendjeddou, Lyamin | Chevallier, Thierry | Masson-Lecomte, Alexandra | Thibault, Constance | Neuzillet, Yann | Audenet, François | Xylinas, Évanguelos | Houédé, Nadine

Edité par CCSD ; Springer Verlag -

International audience. Upper urinary tract urothelial carcinoma (UTUC) is often locally advanced at initial diagnosis and is associated with high recurrence and mortality rates after radical nephroureterectomy (RNU). Adjuvant platinum-based chemotherapy has shown a recurrence-free survival benefit in a randomised phase III trial, while neoadjuvant treatment seems promising in retrospective series. On the contrary, little is known about the role of perioperative immunotherapy and its combination with chemotherapy for UTUC patients, although initial positive results have been published for muscle-invasive bladder cancer.

Consulter en ligne

Suggestions

Du même auteur

Oncological Safety and Diagnostic Yield of Percutaneous Needle-core Biopsies in Upper Tract Urothelial Carcinoma: The UPERCUT Study

Archive ouverte | Prost, Doriane | CCSD

International audience

Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee

Archive ouverte | Masson-Lecomte, Alexandra | CCSD

International audience. Upper urinary tract urothelial carcinoma (UTUC) is an uncommon disease and its gold-standard treatment is radical nephroureterectomy (RNU). Distal ureterectomy (DU) might be an alternative fo...

Instauration du traitement adjuvant endovésical par épirubicine des tumeurs de vessie n'infiltrant pas le muscle : premier retour national d'expérience du CC-AFU vessie

Archive ouverte | Rollin, P. | CCSD

International audience. Introduction: Mitomycin C is the gold standard intravesical adjuvant therapy for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Tensions in the supply of mitomycin have emerged...

Chargement des enrichissements...